View of statins as antimicrobials in cardiovascular risk modification

被引:22
|
作者
Kozarov, Emil [1 ,2 ]
Padro, Teresa [1 ]
Badimon, Lina [1 ,3 ]
机构
[1] Biomed Res Inst St Pau IIB St Pau, Cardiovasc Res Ctr CSIC ICCC, Barcelona 08025, Spain
[2] Columbia Univ, Med Ctr, New York, NY 10032 USA
[3] UAB, Cardiovasc Res Chair, Barcelona, Spain
关键词
Atherosclerosis; Statins; Microbial infection; Inflammation; CHLAMYDIA-PNEUMONIAE INFECTION; ARTERIAL OCCLUSIVE DISEASE; CORONARY-HEART-DISEASE; ACUTE-MYOCARDIAL-INFARCTION; ABDOMINAL AORTIC-ANEURYSMS; SECONDARY PREVENTION TRIAL; RANDOMIZED CLINICAL-TRIAL; A REDUCTASE-ACTIVITY; C-REACTIVE PROTEIN; DOUBLE-BLIND;
D O I
10.1093/cvr/cvu058
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atherosclerosis is a complex arterial pathological development underlying heart attack and stroke and a leading cause of death in developed and now also in developing countries. The primary processes that lead to the inflammatory lipid-laden proliferative lesion, obstructing the blood flow, and referred to as atherosclerotic plaque are dyslipidaemia and inflammation. Here, we will review one of the most efficient classes of drugs indicated for management of cardiovascular disease (CVD), statins. We will assess their pleiotropic effects that emerged from CVD applications, focusing this review specifically on plausible antimicrobial activity. Only recently gaining strength, the recognition of possible antibacterial activity may extend the statin applicability for vascular as well as to other critical inflammatory conditions.
引用
收藏
页码:362 / 374
页数:13
相关论文
共 50 条
  • [1] The Role of Statins in Disease Modification and Cardiovascular Risk in Rheumatoid Arthritis
    Soulaidopoulos, Stergios
    Nikiphorou, Elena
    Dimitroulas, Theodoros
    Kitas, George D.
    FRONTIERS IN MEDICINE, 2018, 5
  • [2] Statins reduce cardiovascular risk
    Mayor, S
    BRITISH MEDICAL JOURNAL, 2002, 325 (7354): : 5 - 5
  • [3] Statins, inflammation and cardiovascular risk
    不详
    EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE, 2023, (197): : 432 - 432
  • [4] RA—lowering cardiovascular risk with statins
    Justin M. S. Lee
    Robin P. Choudhury
    Nature Reviews Rheumatology, 2010, 6 : 123 - 124
  • [5] STATINS AND CARDIOVASCULAR RISK IN RHEUMATIC DISEASES
    Marasini, B.
    Massarotti, M.
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2012, 25 (01) : 25 - 30
  • [6] Statins and cardiovascular risk in type 1 diabetes
    Marcovecchio, Loredana
    HORMONE RESEARCH IN PAEDIATRICS, 2024, 97 : 14 - 15
  • [7] Effectiveness of statins according to cardiovascular risk in the elderly
    Bezin, J.
    Moore, N.
    Mansiaux, Y.
    Steg, P. G.
    Pariente, A.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2018, 32 : 79 - 79
  • [8] Statins for people at low risk of cardiovascular disease
    Zomer, Ella
    Owen, Alice J.
    Magliano, Dianna J.
    Reid, Christopher M.
    LANCET, 2012, 380 (9856): : 1817 - 1817
  • [9] Limitations of the utilization of cardiovascular risk tables and statins
    Palomo, Luis
    Sanchez-Robles, Gabo
    MEDICINA CLINICA, 2015, 144 (07): : 334 - 335
  • [10] The therapeutic role of statins in reducing cardiovascular risk
    Pradelli, Lorenzo
    Eandi, Mario
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2007, 8 : 8 - 12